Novartis Built a Faster Car. The Industry Wants to Skip the Road Entirely.

Another T-Charge product, PHE885, targets BCMA (a protein on myeloma cells) and posted a 100% best overall response rate in the higher-dose cohorts of its Phase 1 trial, though the patient numbers were small. Novartis is also testing T-Charge in autoimmune diseases like lupus and in solid tumors through a partnership with Legend Biotech.

The "Skip the Factory" Crowd

Now here's where it gets interesting. While Novartis refined its factory, at least four companies pushed in vivo CAR-T programs into Phase 1 clinical trials. Their pitch: inject a specially engineered delivery vehicle (a virus or a tiny fat particle called a lipid nanoparticle) directly into the patient. That vehicle finds the patient's T cells, hands them the genetic instructions, and turns them into cancer killers on the spot. No leukapheresis. No cleanroom. No FedEx.

Interius BioTherapeutics (acquired by Gilead for ~$350 million in August 2025) is testing a CD20-targeting in vivo CAR in B-cell cancers. Kelonia Therapeutics landed the first multi-center U.S. trial for a BCMA in vivo CAR-T in myeloma. EsoBiotec (scooped up by AstraZeneca for $425 million) is running its own BCMA Phase 1. And Umoja Biopharma has an early oncology program in the clinic.

Big pharma isn't watching from the sidelines. It's buying tickets to the show. AbbVie paid $2.1 billion for Capstan Therapeutics and its lipid nanoparticle platform. Lilly acquired Orna Therapeutics (circular RNA delivery) in February 2026. BMS grabbed Orbital Therapeutics for $1.5 billion. Five major acquisitions in under a year, all betting that the future of CAR-T might not involve a factory at all.

Novartis Says: Not So Fast

To its credit, Novartis isn't ignoring the threat. Executives have framed T-Charge and in vivo CAR-T as sequential steps on the same innovation ladder, not as competing visions. Mark Rutstein, Novartis's Global Head of Oncology Development, has acknowledged that in vivo data are "encouraging, but early," while emphasizing that T-Charge already has real clinical proof behind it.

The company's quiet hedge? A 2024 partnership with Vyriad to develop a viral vector for in vivo CD19 CAR-T delivery. It's early-stage, preclinical work, but it signals that Novartis knows it can't afford to sit this out entirely.

The strategy has been described as stepwise innovation: first-generation Kymriah, then T-Charge, then in vivo when the science matures. The implicit bet is that T-Charge buys Novartis five to seven years of competitive relevance while in vivo technologies prove themselves.

The Durability Question Nobody Can Answer Yet

Here's the catch that keeps in vivo CAR-T from being a slam dunk. When you build CAR-T cells in a lab, you can measure them, count them, and characterize their fitness before infusing them. With in vivo delivery, the "product" is whatever happens inside the patient after injection. You're trading control for convenience.

Will in vivo-generated CAR-T cells persist long enough to prevent relapse? Will they expand to sufficient numbers in patients whose immune systems are already battered by chemotherapy? Can you avoid accidentally reprogramming the wrong cells (like tumor cells themselves)? These aren't hypothetical worries; they're active research questions with no definitive human answers yet.

There's also the regulatory puzzle. In vivo CAR-T blurs the line between gene therapy and cell therapy. Regulators will likely require up to 15 years of follow-up for integrating viral vectors, given concerns about insertional mutagenesis (the vector accidentally switching on a cancer gene). That's a long regulatory tail, even if the science works.

Who Wins, and When

The honest answer: both platforms will probably coexist for a long time. Analysts project that the first in vivo CAR-T approval won't come before 2030 at the earliest, and mainstream disruption of ex vivo manufacturing is unlikely before the mid-to-late 2030s.

That gives T-Charge a meaningful runway. If Novartis can convert its promising Phase 1 and 2 data into approvals across lymphoma, myeloma, and autoimmune diseases, the platform could anchor Novartis's cell therapy business for the better part of a decade.

But the acquisitions tell a story that's hard to ignore. When five of the world's biggest pharma companies collectively spend billions buying in vivo platforms within a single year, the market is sending a signal. The factory model isn't dead, but the industry is clearly preparing for a world where it's optional.

Novartis built a faster car. It's a really good car. The question is whether the rest of the industry just broke ground on a teleporter.

$290M Says Your Migraine Drugs Aren't Good Enough

A Paragon Biosciences spinout just raised $290 million to go after migraine prevention with a totally different approach. The bet: current drugs leave half of patients undertreated, and a protein called PACAP could be the missing piece.